No profile data available.
Vogenx, Inc. (VOGX) is a listed company, based in Raleigh, United States, with about 4 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$1.45 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $260.86 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D).
Vogenx reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$260.86 million as of October 9, 2026.